Alterity Therapeutics Limited – Sponsored ADR (NASDAQ:ATHE) Sees Significant Decline in Short Interest

Alterity Therapeutics Limited – Sponsored ADR (NASDAQ:ATHE) was the target of a significant decline in short interest during the month of May. As of May 15th, there was short interest totaling 8,051 shares, a decline of 42.1% from the April 30th total of 13,895 shares. Based on an average trading volume of 28,212 shares, the short-interest ratio is presently 0.3 days. Currently, 0.1% of the company’s shares are short sold.

Alterity Therapeutics Stock Performance

NASDAQ ATHE opened at $3.91 on Thursday. Alterity Therapeutics has a 12 month low of $2.66 and a 12 month high of $7.00. The company’s 50-day moving average price is $4.12 and its 200-day moving average price is $3.63.

Institutional Inflows and Outflows

A hedge fund recently bought a new stake in Alterity Therapeutics stock. Citadel Advisors LLC purchased a new position in Alterity Therapeutics Limited – Sponsored ADR (NASDAQ:ATHE) in the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor purchased 22,144 shares of the company’s stock, valued at approximately $83,000. Citadel Advisors LLC owned 0.25% of Alterity Therapeutics as of its most recent filing with the Securities and Exchange Commission. Institutional investors own 2.14% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of equities analysts recently commented on ATHE shares. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Alterity Therapeutics in a research note on Monday, April 20th. Zacks Research raised Alterity Therapeutics to a “hold” rating in a research note on Thursday, February 12th. One analyst has rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, Alterity Therapeutics has a consensus rating of “Hold”.

Alterity Therapeutics Company Profile

Alterity Therapeutics is a clinical-stage biotechnology company focused on the development of novel treatments for neurological and neurodegenerative disorders. The company’s research portfolio centers on small molecules designed to target underlying disease mechanisms, with an emphasis on improving synaptic function and mitigating neuroinflammation.

Among its lead assets is trofinetide (NNZ-2566), a peptide analog derived from insulin-like growth factor 1, which is being investigated for the treatment of Rett syndrome and Fragile X syndrome in ongoing clinical trials.